Our Stocks to Watch today include Signature Devices, Inc. (OTC: SDVI), Neurologix, Inc. (OTCBB: NRGX), MicroIslet, Inc. (OTCBB: MIIS), Silver Falcon Mining, Inc. (OTC: SFMI), OG Nation, Inc. (OTC: OGNA)
Visit http://www.otcpicks.com/ to register for our Daily Market Mover’s Digest Newsletter, and Email Stock Watch Alerts.
SIGNATURE DEVICES (OTC: SDVI)
Detailed Quote: http://www.otcpicks.com/quotes/SDVI.php
Company Profile:
http://www.otcpicks.com/signature-devices/signature-devices.htm
Signature Devices, Inc. engages in the development, manufacture, and sale of information technology products in the United States. The company creates, develops, and publishes 3-D interactive games for consoles and personal computers. It also publishes software for video games and commercial products. The company publishes games for consoles, such as GBA, XBox360, and Playstation. In addition, the company provides consulting for information technology, including computer systems, software, and electronic products. It offers a platform for hardware, embedded systems development, and image generation technology, which can be used in films, videogames, and the military. Further, the company develops customized 3D identities, including lighting, shading, artificial intelligence, and animation systems. Signature Devices was founded in 2002 and is headquartered in Redwood City, California.
SDVI News:
December 12 - Graffiti Entertainment Signs Distribution Agreement With Navarre Distribution Services, Inc.
Signature Devices, Inc. (OTC: SDVI) (www.signaturedevices.com) and their wholly-owned video game development and publishing subsidiary, Graffiti Entertainment, LLC (www.GraffitiEntertainment.com) announced that they have signed an agreement with Navarre Distribution Services, Inc. for the distribution of video games and PC software.
Kenneth Hurley, Signature Devices' Chief Executive Officer stated, "We are pleased that Navarre, a leading distributor of PC software, console games and DVD movies has decided to move forward with us. Through our partnership with Navarre, we expect that market visibility for products will increase significantly as thousands of retailers throughout North America will include our video games and PC software on their shelves and e-commerce websites. The distribution agreement allows us to tap into greater than 6,300 stores and over 100 million people per week that visit these stores. This is great exposure for our products."
NEUROLOGIX INCORPORATED (OTCBB: NRGX)
"Up 19.05% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/NRGX.php
Neurologix, Inc., a development stage company, engages in the research and development of treatments for disorders of the brain and central nervous system primarily utilizing gene therapies. These treatments are designed as alternatives to conventional surgical and pharmacological treatments. The company focuses on gene therapy for treating Parkinson's disease, epilepsy, and other neurodegenerative and metabolic disorders. Its technology, NLX, which is in the clinical development stages, completed a phase I human clinical trial to treat Parkinson's disease. The company was founded in 1999 and is based in Fort Lee, New Jersey.
NRGX News:
December 13 - Neurologix Gene Therapy Approach to Parkinson's Disease Granted Fast Track Designation From FDA
Neurologix, Inc. (OTCBB: NRGX), a biotech company engaged in the research and development of innovative gene therapies for the brain and central nervous system, announced that the U.S. Food and Drug Administration has granted Fast Track Designation for the company’s experimental gene transfer procedure for the treatment of advanced Parkinson’s disease.
The Neurologix procedure delivers a gene (glutamic acid decarboxylase, or GAD) to the subthalamic nucleus of the brain, where it makes an inhibitory neurotransmitter called GABA that helps to quiet the abnormal brain activity that is correlated with motor deficits characterizing Parkinson’s disease. Results of a Phase 1 clinical study showed that the Neurologix gene transfer procedure was both well tolerated and resulted in improved motor function and brain metabolism for patients with advanced Parkinson’s disease over the course of the one-year study. Neurologix is currently preparing to initiate a Phase 2 study of its Parkinson’s disease treatment by early 2008, subject to final FDA consent to the study protocol.
“The FDA’s Fast Track Designation for this gene transfer procedure for Parkinson’s disease recognizes the need for new therapies for patients with advanced Parkinson’s disease who no longer receive adequate benefit from their drug therapies alone,” said John Mordock, President and Chief Executive Officer of Neurologix.
Under the FDA Modernization Act of 1997, Fast Track Designation may facilitate the development and expedite the review of a drug candidate that is intended for the treatment of a serious life-threatening condition and demonstrates the potential to address an unmet medical need for such a condition. Fast Track Designation will provide various means to expedite the development and review of the Neurologix gene transfer procedure for Parkinson’s disease, including the facilitation of meetings and other correspondence with FDA reviewers, consideration for priority review, and the ability to submit portions of a Biologics License Application (BLA) early for review as part of a “rolling” submission. The receipt of Fast Track Designation does not, however, assure the approval of any of Neurologix’s study protocols or the ultimate approval of any BLA that may be submitted by Neurologix to FDA for marketing approval.
MICROLSLET INCORPORATED (OTCBB: MIIS)
"Up 18.87% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/MIIS.php
MicroIslet is a biotechnology company engaged in the research, development, and commercialization of patented technologies in the field of transplantation therapy for patients with insulin-dependent diabetes. MicroIslet has licensed several technologies from Duke University for isolation, culturing, storage, and microencapsulation of insulin-producing islet cells from porcine sources. The Company believes that these technologies, and other proprietary methods developed in-house, are significant advances in the field of transplantation. MicroIslet is exploring possible human clinical trials in both the U.S. and abroad. MicroIslet’s ultimate goal is to offer cell transplantation therapies for diabetic patients worldwide. Additional information about MicroIslet can be found at www.microislet.com.
MIIS News:
December 13 - MicroIslet Holds Positive Pre-IND Meeting for US Based Human Clinical Trial With FDA
MicroIslet, Inc. (OTCBB: MIIS), a biotechnology company engaged in the development and commercialization of transplantation therapies for diabetes, announced that it has met with the U.S. Food and Drug Administration (FDA) to discuss requirements for the filing of an Investigational New Drug (IND) application for MicroIslet-P™, a microencapsulated suspension of pancreatic islet cells.
As a result of the meeting, MicroIslet has clarified details of the development path for its xenotransplantation approach, which involves microencapsulation of insulin producing porcine islet cells. The Company’s last meeting with the FDA in December 2006 related to a proposed IND for allotransplantation of microencapsulated human islet cells. The Company’s current strategy is to proceed directly to human clinical trials of its xenotransplantation approach, which overcomes the inherently limited supply of human islets. The proprietary encapsulation methods used in MicroIslet-PTM are designed to shield the islet cells from immune system rejection, while the planned implantation procedures will be minimally invasive. The Company’s pre-clinical testing to date has demonstrated a strong safety profile for xenotransplantation of porcine islets in rodents and non-human primates.
“MicroIslet appreciates the positive instruction and interactions we received in our pre-IND meeting with the FDA,” said Michael J. Andrews, Chief Executive Officer of MicroIslet. “Their clear advice will greatly assist our IND application planned for the third quarter of 2008, and the subsequent initiation of MicroIslet’s “first in man,” U.S. clinical trial. Based on the meeting, we are excited that a regulatory path is in place for the initiation of MicroIslet’s U.S.-based human clinical trials.”
About MicroIslet-PTM
MicroIslet-PTM consists of microencapsulated porcine islets for implantation into the abdominal cavity using a minimally invasive procedure. Microencapsulation involves surrounding islet cells with formulations of a highly biocompatible, ultra-pure biopolymer, called alginate, or other similar biocompatible polymers. The alginate coating allows insulin, glucose, oxygen and other nutrients to diffuse freely, while blocking antibodies and reducing the patient’s immune response to the implanted islet cells. It is hoped that MicroIslet-PTM will provide physiologic and self-regulating blood glucose control, thus reducing the need for insulin injections or infusions and constant blood glucose monitoring. The long-term complications associated with type 1 diabetes, such as peripheral neuropathies, heart and kidney disease, and skin disorders, may be mitigated by the tighter blood glucose control that would result from such a product.
SILVER FALCON MINING (OTC: SFMI)
"Up 23.08% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SFMI.php
Silver Falcon Mining, Inc. is a junior resource production company specializing in gold and silver properties. Silver Falcon Mining, Inc., has acquired the rights to develop and operate the mines of GoldCorp Holdings, Co., on War Eagle Mountain, situated on the Owyhee Gold Trend of the Silver City Mining District in southern Idaho. The War Eagle properties of GoldCorp Holdings, Co., have produced approximately $ 270 Million in gold and silver to date, and are situated adjacent to the open-pit mines of Kinross Gold Co., (NYSE: KGC), which have produced approximately $ 1.8 Billion in gold and silver. Initial production on the mountain is scheduled for fiscal year 2008, with an estimated 15-20 year life-of-mines. Annual yield, at full capacity, is estimated to be $ 215 Million at $ 650 Gold.
SFMI News:
December 13 - Silver Falcon Mining, Inc.'s (SFMI) Drilling Hits New Mineralized Vein Structure
Silver Falcon Mining, Inc. (OTC: SFMI) released the results of an independent limited drilling program conducted on select areas of War Eagle Mountain, a gold property on which Silver Falcon Mining, Inc. has developmental and operating rights to 14 deep-shaft mines covering the Mountain's primary epithermal Gold and Silver-producing veins.
The independent drilling program was conducted by Donald Tully, P. engineer. "Five angle holes, totaling 684 meters (2,245 feet) were drilled In the Oro Fino area. Two angle holes, totaling 312 meters (1,025 feet) were drilled in the Keystone & Illinois Central area. Three vertical holes, totaling 209 meters (685 feet) were drilled in the Cow Cornice Basin area," wrote Mr. Tully.
Mr. Tully added, "The two holes that were drilled in the Keystone & Illinois Central and North Empire zones of the Central Vein system on the Mountain, approximately midway between the North and South shafts of the Poorman mine, struck extremely strong new veins. These structures showed mineable width indications of mineralization, with results of 1,000 ppm of Gold, or 660 g/t Gold (23.27 oz Gold/ton). It is concluded that the War Eagle Mountain property is an excellent exploration bet in a favorable geological environment for discovering additional and new deposits of precious metals, in addition to mining of the existing deposits."
Mr. Pierre Quilliam, President of Silver Falcon Mining, Inc., said, "The vein structures on War Eagle Mountain clearly extend to depth, and without any evidence of diminishing ore values. The deepest veins discovered, so far, extend to the 610 meters (2,000 foot) level and show values of 64 g/t Gold (2.5 oz Gold/ton) over 2.7 meter (9-foot) widths. We are extremely pleased with the drilling results to date."
Silver Falcon Mining, Inc. is an exploration and development Company specializing in high-grade Gold and Silver mining properties in North America.
OG NATION (OTC: OGNA)
"Up 28.21% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/OGNA.php
OG Nation, Inc. is an innovative new lifestyle company dedicated to building long-term success both through the creation of a unique and recognizable brand name, and through the integration of commercial success with social awareness. Convinced that "success" in business has long been too narrowly defined, OG Nation was founded by a group of visionary beverage industry executives who shared a common goal of leveraging the power of commerce in a way that was consistent with their desire to foster greater inclusion in the business world. Led by their President and Chairman of the Board, the well-known and accomplished Hall-of-Fame tailback, actor, entrepreneur, and social activist Jim Brown, the team of seasoned industry executives have set out to become one of the leaders in the beverage industry through developing, distributing and marketing their signature product lines. For more information, visit the Company website at www.ognation.com.
OGNA News:
December 11 - OG Nation Update: HydroPower Initial Production Phase Completed, Initial Rollout Slated for the New Year
OG Nation, Inc. (OTC: OGNA) announced that in an effort to maintain the greatest possible transparency and to facilitate communication with the market, the Company would like to update its shareholders and potential shareholders on the latest developments in its initial product rollouts. As previously announced, OG Nation is in production of its highly anticipated HydroPower line of advanced flavored waters, with distribution originally scheduled to begin prior to the end of the year. However, due to an unanticipated production issue related to the product labeling, distribution has been rescheduled for initial rollout just after the first of the year. The Company has been inundated with requests for more information about its current plans, and wanted to issue this statement in response to the tremendous level of interest.
According to a Company spokesperson, "We are understandably anxious to see the tangible results of our concerted efforts over this last year come to fruition in the form of our product on retail shelves, but the last thing that we want to do at this point is to allow our eagerness to overcome our better judgment. Because of a minor issue with the labeling, as well as the impending holidays, we felt that it was prudent to take the additional time to ensure that we give HydroPower every opportunity to succeed. We have spent countless hours on product testing, test marketing, and design, and it would be tragic to feel that we had undermined all of our efforts simply to conform to a self-imposed deadline. As it stands right now, the first phase of production is complete, and once the labeling issue has been corrected, we will be able to hit the ground running as we approach the new year."
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover’s Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer:
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:
Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com was compensated seven thousand five hundred dollars in early 2007 by a third party (Silver King Consultants) for a 30 day SDVI IR program, and more recently we have been compensated twenty thousand free trading shares by a third party (TI Consulting). For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor’s sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
